Vanda Pharmaceuticals Inc. (VNDA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US9216591084
Vanda Pharmaceuticals Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 216.11 m USD |
| Gross profit | 203.06 m USD |
| Operating income | -151.17 m USD |
| EBIT | -138.65 m USD |
| Net income | -220.47 m USD |
| Diluted EPS – continuing operations | -3.74 USD |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
More stocks
- Taiwan Sanyo Electric Co Ltd (1614.TW)
- Hyundai Hyms Co., Ltd. (460930.KQ)
- PT Indokripto Koin Semesta Tbk (COIN.JK)
- Quantum-Si Inc (QSI)
- Zilltek Technology Corp (6679.TWO)
- STRATTEC SECURITY CORP (STRT)
- GOLFZON NEWDIN HOLDINGS Co. Ltd (121440.KQ)
- ANY Security Printing PLC (ANY.BD)
- Ace Bed Company Limited (003800.KQ)
- Cardinal Ethanol LLC (CRDE)
- Socep Constant (SOCP.RO)
- Waste Recovery Technology Inc. (6894.TWO)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.